MGB Biopharma Limited

Scottish antibiotics resistance specialist MGB Biopharma Limited is on the verge of moving MGB-BP-3, a completely new class of anti-infective designed to tackle Clostridium difficile , into late-st

Antibiotics resistance specialist MGB Biopharma Ltd. has completed its latest funding round which will enable the Scottish firm toprogress an ongoing Phase IIa clinical trial with its lead antibiotic

While the fight against antimicrobial resistance often produces more lamentation than new products, some long-stalled therapies for the notoriously challenging bacteria Clostridium difficile have re

FDA's push to define a regulatory pathway that will encourage development of drugs for single pathogens could be good news for the handful of companies betting on the approach. The agency is consideri